Atlas Trials

Loxo Oncology, Inc.

17 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Loxo Oncology, Inc.

RecordFirmDate
A Study of Pirtobrutinib (LY3527727 [LOXO-305]) Versus Placebo in Participants With Relapsing Multiple Sclerosis (NCT06104683)Loxo Oncology, Inc.2024-05-01
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT05254743)Loxo Oncology, Inc.2022-07-22
A Study of the Effect of Food on Selpercatinib (LY3527723) in Healthy Participants (NCT05324124)Loxo Oncology, Inc.2022-04-19
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LY3527727) and Rosuvastatin in Healthy Participants (NCT05176314)Loxo Oncology, Inc.2022-01-11
A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants (NCT05136404)Loxo Oncology, Inc.2021-12-03
A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants (NCT05089019)Loxo Oncology, Inc.2021-10-29
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT05023980)Loxo Oncology, Inc.2021-09-23
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT04965493)Loxo Oncology, Inc.2021-09-20
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (NCT04662255)Loxo Oncology, Inc.2021-04-08
Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants (NCT05134337)Loxo Oncology, Inc.2020-02-12
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (NCT04211337)Loxo Oncology, Inc.2020-02-11
Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants (NCT05134350)Loxo Oncology, Inc.2020-02-06
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (NCT03740529)Loxo Oncology, Inc.2019-03-15

Track Loxo Oncology, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.